Clinical Trial

18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-28.
Trial Details
NCT Number NCT07102056
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions Neuroendocrine Tumors
Enrollment 152 participants
Start Date 2026-01-01
Primary Completion 2027-06-03 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-29